comparemela.com

Latest Breaking News On - Faron pharmaceuticals oy chart - Page 1 : comparemela.com

Inside information: Faron Announces First HMA-failed MDS Patient Dosed with Bexmarilimab as part of Phase 2 of BEXMAB Trial Seite 1

09.01.2024 - Phase 2 of the trial aims to recruit 32 patients with HMA-failed MDS and to provide final and optimized dosing for registrational studyCompany is exploring further development opportunities within the bexmarilimab program in hematological cancer . Seite 1

Insider information: Faron Initiates Phase 2 Part of BEXMAB Study of Bexmarilimab in HMA-failed MDS Seite 1

06.11.2023 - MDS patients who have failed prior HMA therapy selected as first indication to advance into Phase 2 3 mg/kg and 6 mg/kg doses selected in accordance with FDA’s Project Optimus initiative guidancePhase 2 part of the study will recruit 32 HMA-failed . Seite 1

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.